Treatment with PDC lung01 induces anti-tumor immune response in significant number of patients which appears to be enhanced by combination with pembrolizumab PDC line Pharma, a clinical stage biotech
Cary Medical Center has received the second year of funding to increase awareness related to Low Dose CT Lung Cancer Screening. The award of $20,000 will help support a broad range of health information activities along with a professional education program in the spring of 2023.
Background
The present study was conducted to assess the renal effects of high dose versus low dose lisinopril in patients with diabetic nephropathy.
Methodology
A prospective observational study was conducted at the Khyber Teaching Hospital, Peshawar, Khyber Pakhtunkhwa, Pakistan, between July 1, 2019, to January 1, 2020. Patients were divided into two groups. Group A patients were administered a low dose (5 mg per day) of Lisinopril and group B were administered a higher dose of therapy (20 mg/day) for three months. At the end of the study, baseline renal functions, electrolytes, and status of microalbuminuria were compared with follow-up values. The primary outcome was to assess the change in microalbuminuria levels in patients at baseline, one month, and three months of therapy.
Results
A total of 72 patients were included in group A (low dose) and 72 patients were enrolled in group B (high dose). The mean ages of group A and group B were 56.3 ± 12.9 years and 53.48
2 chapters with information that could help save thousands if not millions of lives worldwide this winter for those suffering from COVID and Long COVID.